Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 828 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Working to Close the Cancer Screening Gap Caused by COVID May 17, 2022 Joining the dots: How our new research data strategy will unlock... July 7, 2022 2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers June 23, 2021 Facing the future: “How can a 3-year old understand that her... January 12, 2022 Load more HOT NEWS Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined Happy Holidays from the OncoLink Team Man Gets His First Haircut In 15 Years To Join The... People who’ve had radiotherapy shape our new policy calls
